Brainstorm Cell Therapeutics Inc.
BCLI
$0.642
-$0.0032-0.50%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.47% | 17.98% | -52.80% | -25.95% | -22.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.72% | 24.86% | -33.62% | -49.49% | -45.27% |
| Operating Income | 13.72% | -24.86% | 33.62% | 49.49% | 45.27% |
| Income Before Tax | -14.25% | 15.79% | 46.70% | -120.88% | 52.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.25% | 15.79% | 46.70% | -120.88% | 52.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.25% | 15.79% | 46.70% | -120.88% | 52.32% |
| EBIT | 13.72% | -24.86% | 33.62% | 49.49% | 45.27% |
| EBITDA | 13.57% | -26.02% | 33.81% | 49.93% | 45.78% |
| EPS Basic | 37.07% | 42.69% | 67.92% | -22.71% | 73.42% |
| Normalized Basic EPS | 37.07% | 42.70% | 67.92% | -22.76% | 73.42% |
| EPS Diluted | 37.07% | 42.69% | 67.92% | -22.71% | 73.42% |
| Normalized Diluted EPS | 37.07% | 42.70% | 67.92% | -22.76% | 73.42% |
| Average Basic Shares Outstanding | 81.57% | 46.95% | 66.14% | 79.99% | 79.40% |
| Average Diluted Shares Outstanding | 81.57% | 46.95% | 66.14% | 79.99% | 79.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |